Sialorrhea Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Orient Pharma Co., Ltd, Supernus Pharmaceuticals, Inc., NeuroHealing Pharmaceuticals Inc., Merz Pharmaceuticals GmbH, Solstice Neurosciences

DelveInsight's "Sialorrhea Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Sialorrhea epidemiology, market, and clinical development in Sialorrhea. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Sialorrhea market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Sialorrhea Market Share @ Sialorrhea Market Outlook- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Sialorrhea Market Report
• In 7MM, the United States accounts for the highest number of prevalent cases of Sialorrhea in 2023.
• In the United States around 3,36,800 cases of Chronic Sialorrhea in Parkinson's disease were present in 2023.
• Amongst EU4 and the UK, Germany had the highest prevalent population of Sialorrhea, followed by the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population in 2023.
• The leading Sialorrhea Companies such as Orient Pharma Co., Ltd, Supernus Pharmaceuticals, Inc., NeuroHealing Pharmaceuticals Inc., Merz Pharmaceuticals GmbH, Solstice Neurosciences, and others.
• Promising Sialorrhea Pipeline Therapies such as NT 201, Oral Glycopyrrolate Liquid, NH004 tropicamide, MYOBLOC, and others.

Stay ahead in the Sialorrhea Therapeutics Market with DelveInsight's Strategic Report @ Sialorrhea Market Outlook- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sialorrhea Epidemiology Segmentation in the 7MM
• Total Sialorrhea Prevalent Cases of Selected Indications
• Total Prevalent Cases of Sialorrhea in Selected Indications
• Total Prevalent Cases of Chronic Sialorrhea in Selected Indications

Download the report to understand which factors are driving Sialorrhea Epidemiology trends @ Sialorrhea Prevalence- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sialorrhea Marketed Drug
• MYOBLOC (rimabotulinumtoxinB): US WorldMeds
MYOBLOC is the first and only FDA-approved botulinum toxin B for the treatment of chronic Sialorrhea (excessive drooling) in adults. MYOBLOC is an acetylcholine release inhibitor that blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve terminals. MYOBLOC was first approved by the US Food and Drug Administration (FDA) for cervical dystonia in December 2000. US WorldMeds submitted a supplemental biologics license application (sBLA) for the drug to the FDA for the treatment of chronic Sialorrhea in October 2018. MYOBLOC was approved for the condition in August 2019. The drug is marketed in Europe by US WorldMeds' subsidiary Sloan Pharma along with Eisai, under the brand name NEUROBLOC, for the treatment of cervical dystonia. Eisai develops and markets the drug in Japan under the brand name NERBLOC for the same indication.

• XEOMIN: Merz Pharmaceuticals
XEOMIN (incobotulinumtoxinA) for injection is indicated for the treatment of Chronic Sialorrhea in patients 2 years of age and older. In July 2018, the US FDA approved XEOMIN for chronic or excessive drooling (Sialorrhea) in adult patients. In December 2020, Merz Therapeutics announced that the US FDA has approved a sBLA for XEOMIN for the treatment of patients aged 2 years and older with chronic Sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA. XEOMIN gained European approval for treating Chronic Sialorrhea in children in 2021, while its approval for adult patients dates back to 2019.

Transitional Cell Carcinoma Treatment Landscape
Treating Sialorrhea is a difficult process and requires group efforts. The aim is to reduce or stop excess salivation. Current treatment practices vary among practitioners. Traditional treatment options include daily oral medications to diminish saliva production, periodic injections of a medication called Botox for a temporary reduction in saliva production, or a variety of open surgical procedures to remove some salivary glands or disconnect others from the mouth. Thus, the treatment ranges from conservative to more invasive treatment methods. Changes in diet or habits, oral-motor exercises, intra-oral devices such as palatal training devices, and medical treatments such as medication or botulinum toxin injections constitute conservative methods of treatment.

To learn more about Sialorrhea treatment guidelines, visit @ Sialorrhea Treatment Market Landscape- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sialorrhea Market Outlook
Anticholinergic agents like glycopyrrolate are commonly used, with oral solutions like CUVPOSA gaining popularity due to their acceptability among children. Additionally, botulinum toxins, particularly Xeomin, have emerged as effective alternatives with fewer side effects, gaining FDA approval in the US and EMA approval in Europe. Market-wise, the landscape has seen significant shifts, especially with the introduction of MYOBLOC and other botulinum toxin formulations. These approved treatments are expected to dominate the market, reducing the reliance on off-label use of unlicensed products. Furthermore, ongoing research and development, including promising candidates like NT004, and OP-014 indicate a future trend towards targeted therapies with improved efficacy and reduced side effects, shaping a more optimistic outlook for Sialorrhea management.

Learn more about the FDA-approved drugs for Sialorrhea @ Drugs for Sialorrhea Treatment-https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sialorrhea Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Sialorrhea Companies- Orient Pharma Co., Ltd, Supernus Pharmaceuticals, Inc., NeuroHealing Pharmaceuticals Inc., Merz Pharmaceuticals GmbH, Solstice Neurosciences, and others.
• Sialorrhea Pipeline Therapies- NT 201, Oral Glycopyrrolate Liquid, NH004 tropicamide, MYOBLOC, and others.
• Sialorrhea Market Dynamics: Sialorrhea Market Drivers and Barriers
• Sialorrhea Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Sialorrhea Drugs in development @ Sialorrhea Clinical Trials Assessment- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Sialorrhea Report Introduction
3. Executive Summary of Sialorrhea
4. Key Events
5. Sialorrhea Epidemiology and Market Forecast Methodology
6. Sialorrhea Market Overview at a Glance
7. Disease Background and Overview: Sialorrhea
8. Sialorrhea Treatment and Management
9. Sialorrhea Epidemiology and Patient Population
10. Sialorrhea Patient Journey
11. Sialorrhea Marketed Drugs
12. Sialorrhea: 7MM Analysis
13. Sialorrhea Unmet Needs
14. Sialorrhea SWOT Analysis
15. Sialorrhea KOL Views
16. Sialorrhea Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.